Part 4/10:
The advancements from companies like SURGE Therapeutics signal a paradigm shift—from merely treating cancer to aiming for a cure. Their mission aligns with reducing the systemic impact of surgery and enhancing recovery. By integrating immunomodulatory agents into the tumor resection workflow, their approach seeks to prevent cancer recurrence more effectively, potentially transforming patient outcomes significantly.